Halozyme Therapeutics HALO Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's other income (expense)?
- Halozyme Therapeutics (HALO) reported other income (expense) of $1.32M in Q1 2026.
- How has Halozyme Therapeutics's other income (expense) changed year-over-year?
- Halozyme Therapeutics's other income (expense) decreased by 80.7% year-over-year, from $6.82M to $1.32M.
- What is the long-term trend for Halozyme Therapeutics's other income (expense)?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's other income (expense) has grown at a 110.1% compound annual growth rate (CAGR), from $1.1M to $21.47M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.